NewAmsterdam Pharma (NASDAQ:NAMS) Insider Johannes Jacob Piete Kastelein Sells 45,481 Shares

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) insider Johannes Jacob Piete Kastelein sold 45,481 shares of the firm’s stock in a transaction dated Friday, February 20th. The shares were sold at an average price of $35.31, for a total transaction of $1,605,934.11. Following the sale, the insider owned 53,500 shares of the company’s stock, valued at approximately $1,889,085. This represents a 45.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Johannes Jacob Piete Kastelein also recently made the following trade(s):

• On Monday, January 5th, Johannes Jacob Piete Kastelein sold 6,000 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $33.25, for a total transaction of $199,500.00.

NewAmsterdam Pharma Trading Down 0.4%

NAMS traded down $0.16 during trading on Tuesday, hitting $36.01. 755,337 shares of the company’s stock traded hands, compared to its average volume of 702,830. NewAmsterdam Pharma Company N.V. has a 12-month low of $14.06 and a 12-month high of $42.00. The stock has a market capitalization of $4.08 billion, a price-to-earnings ratio of -20.81 and a beta of 0.06. The company’s 50 day simple moving average is $33.98 and its two-hundred day simple moving average is $32.78.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings data on Wednesday, February 18th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.23). NewAmsterdam Pharma had a negative return on equity of 26.67% and a negative net margin of 906.22%.The business had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.92 million. On average, equities analysts expect that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on NAMS shares. Royal Bank Of Canada raised their price objective on shares of NewAmsterdam Pharma from $44.00 to $47.00 and gave the stock an “outperform” rating in a report on Wednesday, January 21st. HC Wainwright upgraded shares of NewAmsterdam Pharma to a “strong-buy” rating in a research report on Thursday, February 19th. Guggenheim lifted their target price on shares of NewAmsterdam Pharma from $41.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, February 19th. Leerink Partners reiterated an “outperform” rating and issued a $55.00 price target on shares of NewAmsterdam Pharma in a research note on Tuesday, January 6th. Finally, Stifel Nicolaus boosted their price objective on NewAmsterdam Pharma from $44.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $47.00.

Institutional Trading of NewAmsterdam Pharma

Institutional investors and hedge funds have recently bought and sold shares of the stock. Wells Fargo & Company MN boosted its holdings in shares of NewAmsterdam Pharma by 50.0% in the 4th quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock worth $32,000 after purchasing an additional 300 shares during the period. Geode Capital Management LLC boosted its stake in NewAmsterdam Pharma by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 102,395 shares of the company’s stock worth $3,590,000 after buying an additional 437 shares during the period. Arizona State Retirement System boosted its stake in NewAmsterdam Pharma by 3.8% during the third quarter. Arizona State Retirement System now owns 13,251 shares of the company’s stock worth $377,000 after buying an additional 483 shares during the period. China Universal Asset Management Co. Ltd. increased its position in NewAmsterdam Pharma by 2.4% during the second quarter. China Universal Asset Management Co. Ltd. now owns 22,549 shares of the company’s stock valued at $408,000 after acquiring an additional 521 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in shares of NewAmsterdam Pharma by 5.3% in the second quarter. The Manufacturers Life Insurance Company now owns 10,868 shares of the company’s stock valued at $197,000 after acquiring an additional 544 shares during the period. 89.89% of the stock is currently owned by institutional investors.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.